In patients who have received neoadjuvant endocrine therapy for localized ER/PR+, HER2 negative breast cancer, how do you decide which patients to offer adjuvant chemotherapy to?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Wisconsin • HR+ • NCI-CCC Breast Tumor Board Question • Neoadjuvant endocrine therapy

What type of adjuvant chemotherapy would you offer?

Would clinically positive lymph nodes or residual disease at time of surgery change your decision?

Answer from: Medical Oncologist at Academic Institution

In a scenario involving neoadjuvant endocrine therapy for someone eligible for adjuvant chemotherapy with residual disease, I propose the following criteria for considering adjuvant chemo: For pathologic stage 3 disease, favor AC-T in this context. Utilize the Oncotype score from the pre-t...

Comments

Medical Oncologist at Siri Onclogy and hematology Infusion Service
Can you tell us what percentage of patients fit th...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
In general, neoadjuvant endocrine therapy (NET) is...

Medical Oncologist at Cancer Spec of Tidewater
In the case of offering NET to patients with high ...

Radiation Oncologist at Universite de Montreal
If the patient has an Oncotype score of 30 done on...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
The predictive data was developed on untreated sam...

Related Questions